Zhu 2005.

Methods	Allocation: randomised, no further details. Blindness: single. Duration: eight weeks. Design: parallel. Setting: inpatient and outpatient, China.
Participants	Diagnosis: schizophrenia (CCMD‐3). BPRS total score of 40 or more. N = 80. Age: aripiprazole group: 16～57 years, mean = (28.3 ± 10.2) years; clozapine group: 17～58 years, mean = (27.8 ± 8.2) years. Gender: aripiprazole group: 22 M, 18 F; clozapine group: 20 M, 20 F. History: aripiprazole group: 2 months～8 years, mean = (6.2 ± 3.7) years; clozapine group: 3 months～9 years, mean = (6.7 ± 5.8) years. Age at onset not reported.
Interventions	1. Aripiprazole: Dose range: 5‐20 mg/day. Mean dose: not reported. N = 40. 2. Clozapine: Dose range: 50‐500 mg/day. Mean dose: not reported. N = 40.
Outcomes	Global state: PANSS score decreased rate (markedly improved: ≥60%, improved: 20%‐59%, no effect: < 20%). Mental state: PANSS total score. PANSS positive subscale score, PANSS negative subscale score, PANSS general pathological subscale score. BPRS total score. Adverse effects.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further details.
Allocation concealment (selection bias)	Unclear risk	Not reported.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Single blind, but whether the blindness was performed well was unclear.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Unclear if outcome was assessed blindly.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	There were drop‐outs, but specific digital was not obtained.
Selective reporting (reporting bias)	High risk	Data on blood and urine routine, liver function were missing.
Other bias	Low risk	None obvious.